Novartis to buy Myricx Bio in up to $1.5bn deal

Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn. The acquisition is expected to close in the second half of 2026, pending customary closing conditions and regulatory approvals. The agreement would enable Novartis to assist in establishing NMTi as a new class of ADC payloads. Credit: Taljat David / Shutterstock.com. Novartis has signed an agreement to purchase Myricx Bio, a UK-based biotechnology company, in a transaction valued at up to $1.5bn. The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. NPVM:…

Source: Pharmaceutical Technology